Meeting
2020 Genitourinary Cancers Symposium
Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866.
Authors
Arlene O. Siefker-Radtke
The University of Texas MD Anderson Cancer Center, Houston, TX
Arlene O. Siefker-Radtke , Gary D. Steinberg , Jens Bedke , Hiroyuki Nishiyama , Xiao Fang , Ritesh Kataria , Blanca Homet Moreno , Christopher J. Hoimes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03924856
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS599)
Abstract #
TPS599
Poster Bd #
N17
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
First Author: Christopher J. Hoimes
Poster
2020 Genitourinary Cancers Symposium
Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011.
First Author: Yohann Loriot
Poster
2020 ASCO Virtual Scientific Program
A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).
First Author: Guru Sonpavde
Poster
2019 ASCO Annual Meeting
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).
First Author: Guru Sonpavde